Best Providers With Labs Included
Programmes that order and pay for bloodwork.
TrimRx leads this ranking at $199 all-in monthly at a 2.4 mg maintenance dose and about $2,388 for a first year. The order is computed from the dataset on the criterion named in the title, not assigned editorially.
1 of 20 priced programmes qualify for this list; 19 are excluded because they do not meet the criterion. Programmes that publish no price we could capture cannot be ranked and are listed separately.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
Of the 32 programmes on this site, 4 have a price we read at the provider or manufacturer, 16 carry a third-party figure we have not confirmed, and 12 publish no price we can interpret. Every table shows which is which, because a comparison that mixes them without saying so is not a comparison.
Best Providers With Labs Included
| Programme | All-in at 2.4 mg | First year | Structure | Evidence |
|---|---|---|---|---|
| 1. TrimRx | $199 | $2,388 | flat at every doseno membership | third-party figure |
How this ranking is produced
The sort key is stated in the title and applied to the dataset. Nothing is weighted by hand, no programme pays for position, and the underlying figures are downloadable from the price index so the order can be reproduced rather than trusted. Where a programme is excluded, it is because it fails the criterion, not because of an editorial judgement about it.
What this ranking cannot tell you
Whether shipments arrive on time, whether messages get answered, or whether the clinical oversight is adequate. We hold no measurements of those we would defend, so they are absent rather than estimated. Read the individual review and run the pharmacy checks before enrolling anywhere this list surfaces.
How wide the spread actually is
Between the top and bottom of this list the difference is $0 on the criterion being ranked. TrimRx leads and TrimRx sits last among those that qualify, for the identical molecule from the same category of licensed pharmacy.
That spread is not explained by the medicine. It is overhead, clinical wrap, pharmacy sourcing, marketing cost and margin. Knowing that is what makes shopping this category worthwhile at all: there is real money on the table and no clinical reason to leave it there.
What this ranking deliberately ignores
Shipping reliability, response times, clinical depth and how a programme behaves when something goes wrong. We hold no measurements of those we would defend, so they are absent rather than estimated, and no weighting has been applied to smuggle a judgement about them into the order.
That makes this list narrower than an editorial round-up and considerably harder to dispute. It answers one question exactly, and it says which question in the title.
Using a ranking without being misled by one
Set the dose you expect to maintain on, filter to prices we verified at source, and read the individual review of anything in the top three before enrolling. A ranking is a shortlist generator, not a recommendation, and the differences that decide satisfaction are mostly not the ones a ranking can measure.
Then re-run it annually. Programmes move pricing without telling existing patients, and several tracked programmes changed rates more than once in the past year.
The same 1 programmes at every dose
A ranking sorted at one dose is a ranking of one scenario. This is the qualifying field at the starter dose, a maintenance dose and the ceiling, so you can see whether the order holds.
| Programme | At 0.25 mg | At 1 mg | At 2.4 mg | First year | Evidence |
|---|---|---|---|---|---|
| TrimRx | $199 | $199 | $199 | $2,388 | third-party figure |
The spread between first and last on this criterion is $0. Where the order changes between columns, the programme you should choose depends on a dose decision your prescriber has not made yet — which is an argument for the flat-rate options rather than for the top of this table.
What the leader is not
TrimRx leads on the criterion in the title. That is not a statement that it ships reliably, answers messages quickly, or provides better clinical oversight than the programme below it. We hold no measurements of any of those and will not imply otherwise by dressing a price sort as an overall verdict.
What it does mean is that on one stated, reproducible measure it comes first, and you can download the file and confirm that in under a minute.
Who this ranking is wrong for
Anyone whose binding constraint is not the one in the title. A cheapest-at-maintenance list is the wrong list for someone holding a starter dose permanently. A no-membership list is the wrong list for someone who would use unlimited clinician messaging weekly during titration.
There are more than twenty rankings on this site precisely because there is no single best programme. Pick the ranking that matches your constraint, then read the individual review.
How often this changes
Pricing in this market moved repeatedly through 2026 and five large programmes stopped selling compounded semaglutide entirely. This table regenerates from the dataset on every build rather than being edited, so it cannot silently drift, but the underlying capture date is 2026-08-05.
Treat any ranking older than a month — ours included — as needing a re-check against the provider's own page before you act on it.
How to use a ranking without being used by one
Read the criterion in the title, then check it is your criterion. This list sorts on one measure; there are more than twenty rankings here because no single measure decides a purchase.
Then read the second and third entries as seriously as the first. The gap between them is frequently smaller than the difference in what they disclose, and a programme two places down that names its pharmacy is a better purchase than the leader that does not.
Finally, check the evidence column. TrimRx leads here, and whether its figure was read at the provider or taken from a third party is stated in the row rather than buried in a methodology page.
Why we publish so many of these
Because a single 'best' list is a claim that everyone shares one constraint, which is obviously false. Someone holding 1 mg permanently, someone escalating to 2.4 mg, someone who cannot commit to a term and someone with a documented cardiovascular indication are four different buyers.
Splitting them into separate rankings costs us the ability to say 'the best programme is X', which is the sentence comparison sites are built to sell. It buys the reader an order that matches their situation.
If your constraint is not represented, the matrix sorts the same dataset on any column.
What would move this list
A price change we have not captured, a programme leaving the compounded market, or a figure we recorded from a third party that does not survive checking. All three happened during 2025 and 2026, and all three are logged with the date when they do.
The table regenerates from the dataset on every build rather than being edited by hand, so it cannot silently drift from the underlying record. Prices were captured 2026-08-05.
Where best providers with labs included sits in the sequence
Order matters more than most guidance admits. Establish coverage first, because a covered prescription under a documented indication beats every cash route here. Then establish the dose you expect to hold. Only then compare prices.
Most people do this backwards — compare prices, enrol, then discover an indication they already qualified for. Semaglutide has more of those routes than most weight-management drugs: type 2 diabetes, cardiovascular risk reduction, and a liver indication for a narrow population.
The check that costs nothing
Ask which pharmacy fills the prescription and search your state board's licensee register for it. Two minutes, free, and possible for only 6 of the 20 priced programmes because the rest do not name one.
A name and a licence number is the good answer. A category is incomplete but honest. A deflection about proprietary partnerships is the answer.
Why this matters more here than for approved medicines
An approved product has been reviewed before marketing and is made under a federal quality system with supply-chain traceability. A compounded preparation has not been through that review. Its assurance comes from the pharmacy, the state board licensing it, and at good operations batch testing for sterility and potency.
That is a legitimate framework rather than a loophole, and it moves verification work onto you. It is the honest reason the compounded price is lower.
What this page assumes about you
That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.
Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 20 cash prices spanning $145 to $324.
The bias we can see in our own data
We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.
It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 12 tracked programmes appear here with an explanation instead of a number because of it.
What we deliberately do not measure
Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.
That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.
The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.
The switching cost nobody prices
Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.
The second is expensive. Sixteen weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.
The comparison most people get wrong
Almost every published semaglutide ranking sorts on advertised entry price. That figure describes the four weeks you spend at the 0.25 mg starter dose — roughly 8% of a first year. Ten of your first twelve months are spent at or near a maintenance dose, which is why every figure here is stated at 2.4 mg and why the first-year column exists.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.
Common questions
Which programme leads on providers with labs included?
TrimRx at $199 all-in monthly at a 2.4 mg maintenance dose and about $2,388 for a first year. The order is computed from the dataset on the criterion in the title, not assigned.
Is this ranking paid for?
No. No programme pays for placement or position, and the order is generated from the published dataset, which is downloadable so the ranking can be reproduced.
Why are some programmes missing from this list?
Either they fail the criterion for this list, or they publish no price we could capture. The second group appears in the provider directory with an explanation instead of an estimated figure.
How current are these prices?
Captured 2026-08-05. Each row carries an evidence status saying whether we read the figure at the provider or took it from a third party.
Does the ranking change with my dose?
Yes, on any list sorted at a maintenance dose. Flat-rate programmes hold one price at every strength while dose-scaled programmes climb, so the order at 0.25 mg is frequently not the order at 2.4 mg.